<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896373</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI18/RFPL</org_study_id>
    <secondary_id>2019-A00394-53</secondary_id>
    <nct_id>NCT03896373</nct_id>
  </id_info>
  <brief_title>Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus</brief_title>
  <acronym>RFPL</acronym>
  <official_title>Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the expression of the neonatal fc receptor (FcRn) in white blood cells
      and antigen-presenting cells (APC) in active lupus patients compared to inactive lupus
      patients and control to investigate if it's upregulated or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FcRn is an intracellular receptor which binds the Fc of immunoglobulins G (IgG) and albumin
      which induce an upgraded half-life of this two proteins.

      It's extended role involve the regulation of immune complexes and anti-tumoral immunity, some
      studies showing a direct correlation between it's expression and the tumor surface and
      prognosis.

      Recently a role in the upregulation of humoral response with a increase of the antibodies's
      diversity and a more efficient priming of lymphocyte B have been evocated.

      The lupus erythematosus is an auto-immune disease mediated by IgG and immune complexes
      characterized by a high diversity of autoantibodies and a large dysregulation of the immune
      system in all it's components.

      In this study, by analogy with the founding in anti-tumoral immunity, the investigators
      hypothesised that in an active lupus disease the expression of FcRn is upregulated in the
      white blood cells and in APC.

      This is followed by an extended half life of IgG autoantibodies and immune complexes inducing
      direct damages by their deposit in tissues and indirectly by upregulating the humoral
      response, leading to anormal production of a large panel of autoantibodies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of FcRn in active or newly diagnosed lupus erythematosus compared with inactive lupus erythematosus</measure>
    <time_frame>At baseline</time_frame>
    <description>Measurement in flow cytometry of the fluorescence's mean of FcRn in each type of white blood cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FcRn genotyping (FCGRT)</measure>
    <time_frame>At baseline</time_frame>
    <description>FcRn gene polymorphism analysis (FCGRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGHG1 genotyping</measure>
    <time_frame>At baseline</time_frame>
    <description>IGHG1 gene polymorphism analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of FcRn in CD16 monocytes</measure>
    <time_frame>At baseline</time_frame>
    <description>CD16 is used to differentiate subpopulation of monocytes. The investigators will evaluate the correlation between expression of CD16 and the fluorescence's mean of FcRn measured in flowcytometry.
This measure will be done for each population of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of FcRn in macrophages</measure>
    <time_frame>At baseline</time_frame>
    <description>After a positive selection of monocytes obtained from participants, the investigators will measure the fluorescence's mean of FcRn in this cells for each population of participants</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Lupus erythematosus</arm_group_label>
    <description>Patients with inactive lupus erythematosus, active lupus erythematosus or newly diagnosed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples</description>
    <arm_group_label>Lupus erythematosus</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples from patients
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patient included are hospitalised in the university hospital of Tours in France
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Lupus erythematosus newly diagnosed or active

          -  Inactive lupus erythematosus

          -  Needing a blood sample for diagnosis or follow up

          -  Signed informed consent

        Exclusion criteria:

          -  Other auto immune disease

          -  Pregnant or brest feeding

          -  Legal protection or protected adults
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie GOUILLEUX, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie GOUILLEUX, PhD</last_name>
    <phone>02 34 37 89 13</phone>
    <phone_ext>+33</phone_ext>
    <email>valerie.gouilleux@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanis RAMDANI, MD</last_name>
    <phone>02 47 47 87 36</phone>
    <phone_ext>+33</phone_ext>
    <email>yanis.ramdani@etu.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dermatology Service, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MACHET, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent MACHET, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Service, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François MAILLOT, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>François MAILLOT, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology Service, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle BARBET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christelle BARBET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumatology Service, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe GOUPILLE, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe GOUPILLE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

